Low-dose dobutamine stress 99mtc tetrofosmin quantitative gated spect performed during the acute phase of myocardial infarction predicts subsequent myocardial viability and detects stunned myocardium

Nuclear Medicine Communications

Volumn 24, Issue 2, 2003, Pages 167-174

  Kasama, S ^a   Toyama, T ^a   Kumakura, H ^a   Takayama, Y ^a   Ichikawa, S ^a   Suzuki, T ^a   Kurabayashi, M ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Dobutamine; Gated SPECT; Myocardial viability; Tetrofosmin

Indexed keywords

DIAGNOSTIC AGENT; DOBUTAMINE; ORGANOPHOSPHORUS COMPOUND; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M 1,2 BIS(BIS(2 ETHOXYETHYL)PHOSPHINO)ETHANE; TECHNETIUM TC 99M 1,2-BIS(BIS(2-ETHOXYETHYL)PHOSPHINO)ETHANE;

ACUTE DISEASE; AGED; ARTICLE; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING ORGAN SYSTEMS; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GATED IMAGING; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART VENTRICLE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STRESS; STUNNED HEART MUSCLE;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; DOBUTAMINE; FEMALE; FOLLOW-UP STUDIES; GATED BLOOD-POOL IMAGING; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL STUNNING; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STRESS; STROKE VOLUME; TISSUE SURVIVAL; VENTRICULAR DYSFUNCTION, LEFT;

EID: 85047277363     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200302000-00009     Document Type: Article

References (36)

1. Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation 1982; 66: 1146-1149.
2. Wijns W, Vatner SF, Camici PG. Hibernating myocardium. N Engl J Med 1998; 339: 173-181.
3. Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986; 314: 884-888.
4. Tuttle RR, Mills J. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res 1975; 36: 185-196.
5. Pierard LA, De Landsheere CM, Berthe C, Rigo P, Kulbertus HE. Identification of viable myocardium by echocardiography during dobutamine infusion in patients with myocardial infarction after thrombolytic therapy: comparison with positron emission tomography. J Am Coll Cardiol 1990; 5: 1021-1031.
6. Cigarroa CG, deFilippi CR, Brickner ME, Alvarez LG, Wait MA, Grayburn PA. Dobutamine stress echocardiography identifies hibernating myocardium and predicts recovery of left ventricular function after coronary revascularization. Circulation 1993; 88: 430-436.
7. Germano G, Kavanagh PB, Su HT, Mazzanti M, Kiat H, Hachamovitch R, et al. Automatic reorientation of three-dimensional, transaxial myocardial perfusion SPECT images. J Nucl Med 1995; 36: 1107-1114.
8. Germano G, Kiat H, Kavanagh PB, Moriel M, Mazzanti M, Su HT, et al. Automatic quantification of ejection fraction from gated myocardial perfusion SPECT. J Nucl Med 1995; 36: 2138-2147.
9. Germano G, Erel J, Lewin H, Kavanagh PB, Berman DS. Automatic quantitation of regional myocardial wall motion and thickening from gated technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. J Am Coll Cardiol 1997; 30: 1360-1367.
10. Yamagishi H, Akioka K, Hirata K, Sakanoue Y, Toda I, Yoshiyama M, et al. Dobutamine stress electrocardiography-gated Tc-99m tetrofosmin SPECT for detection of viable but dysfunctional myocardium. J Nucl Cardiol 2001; 8: 58-67.
11. Yamagishi H, Akioka K, Hirata K, Sakanoue Y, Toda I, Yoshiyama M, et al. Detection of a biphasic response of hibernating myocardium by dobutamine-stress electrocardiography-gated technetium-99m-tetrofosmin single photon emission computed tomography-a case report. Jpn Circ J 1999; 63: 688-691.
12. The Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med 1983; 309: 331-336.
13. Reduto LA, Freund GC, Gaeta JM, Smalling RW, Lewis B, Gould KL. Coronary artery reperfusion in acute myocardial infarction: beneficial effects of intracoronary streptokinase on left ventricular salvage and performance. Am Heart J 1981; 102(6, Pt 2): 1168-1177.
14. Stack RS, Phillips 3rd HR, Grierson DS, Behar VS, Kong Y, Peter RH, et al. Functional improvement of jeopardized myocardium following intracoronary streptokinase infusion in acute myocardial infarction. J Clin Invest 1983; 72: 84-95.
15. Topol EJ, Weiss JL, Brinker JA, Brin KP, Gottlieb SO, Becker LC, et al. Regional wall motion improvement after coronary thrombolysis with recombinant tissue plasminogen activator: importance of coronary angioplasty. J Am Coll Cardiol 1985; 6: 426-433.
16. Satler LF, Kent KM, Fox LM, Goldstein HA, Green CA, Rogers WJ, et al. The assessment of contractile reserve after thrombolytic therapy for acute myocardial infarction. Am Heart J 1986; 111: 821-825.
17. Grines CL, O'Neill WW, Anselmo EG, Juni JE, Topol EJ. Comparison of left ventricular function and contractile reserve after successful recanalization by thrombolysis versus rescue percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1988; 62: 352-357.
18. Sheehan FH, Mathey DG, Schofer J, Krebber HJ, Dodge HT. Effect of interventions in salvaging left ventricular function in acute myocardial infarction: a study of intracoronary streptokinase. Am J Cardiol 1983; 52: 431-438.
19. Rogers WJ, Hood Jr WP, Mantle JA, Baxley WA, Kirklin JK, Zorn GL, et al. Return of left ventricular function after reperfusion in patients with myocardial infarction: importance of subtotal stenoses or intact collaterals. Circulation 1984; 69: 338-349.
20. Christian TF, Behrenbeck T, Pellikka PA, Huber KC, Chesebro JH, Gibbons RJ. Mismatch of left ventricular function and infarct size demonstrated by technetium-99m isonitrile imaging after reperfusion therapy for acute myocardial infarction: identification of myocardial stunning and hyperkinesia. J Am Coll Cardiol 1990; 16: 1632-1638.
21. White HD, Norris RM, Brown MA, Takayama M, Maslowski A, Bass NM, et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987; 317: 850-855.
22. O'Rourke M, Baron D, Keogh A, Kelly R, Nelson G, Barnes G, et al. Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator. Circulation 1988; 77: 1311-1315.
23. Ritchie JL, Cerqueira M, Maynard C, Davis K, Kennedy JW. Ventricular function and infarct size: the Western Washington Intravenous Streptokinase in Myocardial Infarction Trial. J Am Coll Cardiol 1988; 11: 689-697.
24. 99mTc 2-methoxy-isobutyl-isonitrile. A direct comparison in normal individuals and patients with coronary artery disease. Circulation 1989; 79: 1282-1293.
25. Higley B, Smith FW, Smith T, Gemmell HG, Das Gupta P, Gvozdanovic DV, et al. Technetium-99m-1,2-bis[bis(2-ethoxyethyl) phosphino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med 1993; 34: 30-38.
26. Platts EA, North TL, Pickett RD, Kelly JD. Mechanism of uptake of technetium-tetrofosmin. I: Uptake into isolated adult rat ventricular myocytes and subcellular localization. J Nucl Cardiol 1995; 2: 317-326.
27. Yamagishi H, Akioka K, Hirata K, Sakanoue Y, Toda I, Yoshiyama M, et al. Dobutamine-stress electrocardiographically gated positron emission tomography for detection of viable but dysfunctional myocardium. J Nucl Cardiol 1999; 6: 626-632.
28. Andy JJ, Curry CL, Ali N, Mehrotra PP. Cardiovascular effect of dobutamine in severe congestive heart failure. Am Heart J 1977; 94: 175-182.
29. Leier CV, Unverferth DV. Drugs five years later. Dobutamine. Ann Intern Med 1983; 99: 490-496.
30. Meyer SL, Curry GC, Donsky MS, Twieg DB, Parkey RW, Willerson JT. Influence of dobutamine on hemodynamics and coronary blood flow in patients with and without coronary artery disease. Am J Cardiol 1976; 38: 103-108.
31. Mikulic E, Cohn JN, Franciosa JA. Comparative hemodynamic efforts of inotropic and vasodilator drug in severe heart failure. Circulation 1977; 56: 528-533.
32. Leier CV, Unverferth DV, Kates RE. The relationship between plasma dobutamine concentrations and cardiovascular responses in cardiac failure. Am J Med 1979; 66: 238-242.
33. Kates RE, Leier CV. Dobutamine pharmacokinetics in severe heart failure. Clin Pharmacol Ther 1978; 24: 537-541.
34. Vasu MA, O'Keefe DD, Kapellakis GZ. Myocardial oxygen consumption: effects of epinephrine, isoproterenol, dopamine, norepinephrine, and dobutamine. Am J Physiol 1978; 235: H237-241.
35. Chin BB, Esposito G, Kraitchman DL. Myocardial contractile reserve and perfusion defect severity with rest and stress dobutamine (99m)Tc-sestamibi SPECT in canine stunning and subendocardial infarction. J Nucl Med 2002; 43: 540-550.
36. Afridi I, Kleiman NS, Raizner AE, Zoghbi WA. Dobutamine echocardiography in myocardial hibernation. Optimal dose and accuracy in predicting recovery of ventricular function after coronary angioplasty. Circulation 1995; 91: 663-670.